Trial Profile
A Phase 1 Multicenter, Dose Escalation, Cohort Extension and Dose and Disease Expansion Study of APL-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Geptanolimab (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Apollomics
- 05 May 2022 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2021 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 07 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.